Eleven hypercalceic patients affected by various kinds of cancer were treated with dichloromethylene diphosphonate (Cl2MDP), 400 mg diluted in 500 ml of saline solution, i.v., during 3 h. Drug administration normalized plasma calcium levels in all treated patients, within 72 h for patients with lung cancer; within a longer period for other kinds of cancer. Moreover, Cl2MDP also reduced calciuria in treated patients. The use of the drug was not followed by side effects and was also well tolerated in patients with kidney insufficiency.
Get full access to this article
View all access options for this article.
References
1.
ChantraineA., JungA., van OuwenallerCh., DonathA.: Le dichlorométhylène-diphosphonate dans le traitement des métastases osseuses lytiques.Nouv. Presse Méd., 13: 479–482, 1984.
2.
CharhonS., ChapuyM.C., Valentin-OpranA., EdouardC., RosiniS., MeunierP.J.: Traitement de l'hypercalcémie d'origine myélomateuse par les diphosphonates intraveineux.Nouv. Presse Méd., 12: 2983–2986, 1983.
3.
ConteN., Di VirgilioR., RoiterI.: Normalizzazione pre-operatoria di ipercalcemia da carcinoma paratiroideo con somministrazione endovenosa di diclorometilen-difosfonato.Minerva Endocrinol., 9: 47–48, 1984.
4.
DelmasP.D., ChapuyM.C., VignonE., BrianconD., CharhonS., MeunierP.J.: Traitement de l'hypercalcémie d'origine métastatique osseuse par le dichlorométhylène diphosphonate.Nouv. Presse Méd., 19: 1471–1474, 1982.
5.
DelmasP.D., ChapuyM.C., VignonE., CharhonS., BrianconD., AlexandreC., EdouardC., MeunierP.J.: Long-term effects of dichloromethylene diphosphonate in Paget's disease of bone.J. Clin. Endocrinol. Metab., 54: 837–844, 1982.
6.
ElomaaI., GröhnP., BlomquistC., PorkkaL., KairentoA.L., SelanderK., Lambert-AllardtC., HolmströmT.: Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases.Lancet, 1: 146–148, 1983.
7.
FleishH., RussellR.G.G., FrancisM.D.: Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo.Science, 165: 1262–1264, 1969.
8.
JacobsT.P., SirisE.T., BilezikianJ.P., BaquiranD.C., ShaneE., CanfieldR.E.: Hypercalcemia of malignancy: treatment with intravenous dichloromethylene diphosphonate.Ann. Inter. Med., 94: 312–316, 1981.
9.
JungA., ChantraineA., DonathA., van OuwenallerC., TurnillD., MermillodB., KitlerM.E.: Use of dichloromethylene diphosphonate in metastatic bone disease.N. Engl. J. Med., 308: 1499–1501, 1983.
10.
MundyG.R., WilkinsonR., HeathD.A.: Comparative study of available medical therapy for hypercalcemia of malignancy.Am. J. Med., 74: 421–432, 1983.
11.
PatersonA.D., KanisA., CameronE.C., DouglasD.L., BeardD.J., PrestonF.E., RussellG.G.: The use of dichloromethylene diphosphonate for the management of hypercalcemia in multiple myeloma.Br. J. Haematol., 54: 121–132, 1983.
12.
SirisE.S., HymanG.A., CanfieldR.E.: Effect of dichloromethylene diphosphonate in women with breast carcinoma metastatic to the skeleton.Am. J. Med., 74: 401–406, 1983.
13.
SirisE.S., ShermanW.H., BaquiranD.C., Schlat-tererJ.P., OssermanE.F., CanfieldR.E.: Effects of dichloromethylene diphosphonate on skeletal mobilization of calcium in multiple myeloma.N. Engl. J. Med., 302: 310–315, 1980.
14.
SleeboomH.P., BijvoetO.L., van OosteromA.T., GleedJ.H., O'RiordanJ.L.H.: Comparison of intravenous (3-amino-1-hydroxypropylidene)-1, 1-bi-phosphonate and volume repletion in tumor-induced hypercalcemia.Lancet, 1: 239–243, 1983.
